Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 05, 2020 16:05 ET | Source: CymaBay Therapeutics, Inc.

CymaBay Reports Third Quarter 2020 Financial Results and Provides Corporate Update

CymaBay announces trial design for RESPONSE, a global phase 3 registration study for seladelpar in primary biliary cholangitis (PBC) Results from the ENHANCE phase 3 study evaluating seladelpar for...
November 05, 2020 08:00 ET | Source: CymaBay Therapeutics, Inc.

CymaBay Announces Study to Evaluate the Potential for GPR119 Agonists to Prevent Hypoglycemia in Type 1 Diabetes

NEWARK, Calif., Nov. 05, 2020 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic...
November 02, 2020 08:00 ET | Source: CymaBay Therapeutics, Inc.

CymaBay Therapeutics Announces an Oral Late-Breaking Presentation of Results from the ENHANCE Global Phase 3 Study Evaluating Seladelpar for Primary Biliary Cholangitis at The Liver Meeting® 2020

NEWARK, Calif., Nov. 02, 2020 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing and providing access to innovative therapies for...
October 30, 2020 16:32 ET | Source: CymaBay Therapeutics, Inc.

CymaBay Therapeutics to Report Third Quarter 2020 Financial Results on Thursday, November 5, 2020

NEWARK, Calif., Oct. 30, 2020 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic...
October 01, 2020 08:00 ET | Source: CymaBay Therapeutics, Inc.

CymaBay Therapeutics to Present Data from its Phase 2 Study of Seladelpar in Patients with NASH at The Liver Meeting® 2020

NEWARK, Calif., Oct. 01, 2020 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing and providing access to innovative therapies for...
September 03, 2020 16:05 ET | Source: CymaBay Therapeutics, Inc.

CymaBay Therapeutics to Present at Upcoming Investor Conferences

NEWARK, Calif., Sept. 03, 2020 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic...
August 27, 2020 08:00 ET | Source: CymaBay Therapeutics, Inc.

CymaBay Therapeutics Presents Positive Final Results From 52-Week Phase 2 Study in Primary Biliary Cholangitis at The Digital International Liver Congress™ 2020

Sustained anti-cholestatic and hepatoprotective effects observed in patients with and without cirrhosisSelf-reported pruritus improved at one year for patients in highest categories of baseline...
August 20, 2020 08:00 ET | Source: CymaBay Therapeutics, Inc.

CymaBay Therapeutics Announces Presentations During The Digital International Liver Congress™ 2020

NEWARK, Calif., Aug. 20, 2020 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing and providing access to innovative therapies for...
August 10, 2020 16:01 ET | Source: CymaBay Therapeutics, Inc.

CymaBay Reports Second Quarter 2020 Financial Results and Provides Corporate Update

FDA lifts all clinical holds on seladelpar Positive topline data announced from ENHANCE Company to reinitiate clinical development of seladelpar for patients with PBC Cash sufficient to fund...
August 03, 2020 16:01 ET | Source: CymaBay Therapeutics, Inc.

CymaBay Therapeutics to Report Second Quarter 2020 Financial Results on Monday, August 10, 2020

NEWARK, Calif., Aug. 03, 2020 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right